Cabaletta Bio: warrant exercises bring in $128.2 million in gross proceeds
Cabaletta Bio said holders exercised warrants from its June 2025 underwritten public offering, bringing aggregate gross proceeds to approximately $128.2 million through the September 12, 2026 expiration date. Most of that total, 46,011,900 warrants for approximately $115.0 million, was exercised from July 1, 2026 through expiration. For shareholders, the exercises add cash to the company at a fixed exercise price of $2.50 per share.
Key points
- Warrants issued in the June 2025 offering: 53,090,190, each with an exercise price of $2.50 per whole share
- From July 1, 2026 through September 12, 2026: 46,011,900 warrants exercised for approximately $115.0 million in gross proceeds
- Total gross proceeds from exercises through the expiration date: approximately $128.2 million, including $13.2 million from 5,275,100 warrants exercised through June 30, 2026
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.